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Background. Aim of present investigation was to analyze survival and recurrence rate in patients with active endocarditis referred
to our centre for surgical treatment. Methods. 80 consecutive patients with active infective endocarditis (52 males, 28 females,
mean age 59.2 years) were referred to our institution for surgical treatment. 78 patients underwent surgery, and 2 patients died
before intervention. Results. Fifty patients had native valve endocarditis, 30 prosthetic valve involvement. Hospital mortality has
been 10.2%. Three discharged patients (4.9%) died at an average 18-month followup. Endocarditis recurred in 4 (2 being S. aureus
prosthetic tricuspid endocarditis in drug addicts). All patients who underwent valve repair or homograft implant were alive and
freeofrecurrence.Conclusions.Ourresultssuggestthatwithpropersurgicaltreatmentpatientswithactiveendocarditis discharged
alive from hospital have a survival >90% at 18 months with a low recurrence rate.
1.Introduction
Surgery is the treatment of choice in complicated prosthetic
valves endocarditis [1, 2], and sterilization and “cure” by
medical treatment alone are rarely possible in active infective
endocarditis (IE) on native valves [3]. Residual valve damage
may be associated with signiﬁcant hemodynamic changes
leading to a decreased life expectancy. Surgical treatment
has been demonstrated to be the only independent predictor
of long-term survival in a large study conducted in France
on patients admitted to hospital for IE [4]. Recently a large
multicentric study showed that surgery was associated with a
decreased risk of both in-hospital and late mortality [5].
In the active phase of illness guidelines suggest an early
surgical approach, associated with and followed by antibiotic
therapy for 6–8 weeks after surgery [6]. The purpose of
our study was to assess hospital mortality, recurrence rate
of endocarditis, and midterm survival (average followup 18
months) in patients consecutively referred in a period of
4 years to Florence Heart Surgery Department for surgical
treatment of active endocarditis.
2.MaterialandMethods
Inthestudywereincluded80consecutivepatientsreferredto
our institution between January 1, 2003 and December 31,
2006 for surgical treatment of active infective endocarditis
[7]. Mean age was 59,5 years (range 22–84 years). There
was a male prevalence (50/30), and men were on average
6 years younger than women (57.5 versus 63.1 years)
(Table 1). Sixty-eight percent were referred by primary or
second level hospitals of Tuscany, while the other 32% from
the emergency department of our hospital. Fifty patients
suﬀeredfromnativevalveendocarditis—NVE—(62%)while
30 were aﬀected by prosthetic valve endocarditis—PVE—
(38%). Early PVE, deﬁned as an infection occurring within 1
year after valve replacement, accounted for 40% of PVE. Late
prosthetic valve endocarditis occurred in 18 patients.2 ISRN Cardiology
Table 1: Clinical characteristics of patients included in the study.
Mean age (±SD)
Overall no 80 59.5 ± 16.1
Men no 50 57.3 ± 15.8
Women no 30 63.1 ± 16.8
Type of valve involvement no
Native valve endocarditis 50
Prosthetic valve endocarditis 30
Valve involved no
Mitral 28
Aorta 38
Tricuspid 4
Mitral + aorta 10
NYHA Class no
IV 21
III 23
II 14
I2 2
At admission in our department patients underwent
accurate history collection; physical examination with par-
ticular attention to heart, neurological ﬁndings, skin or
ocularmanifestations,historyorclinicalevidenceofsystemic
embolism; assessment of vital signs, measurement of body
temperature, ECG, and laboratory examinations (haemoglo-
bin concentration, leukocyte count, serum creatinine). At
least 3 samples for blood cultures were collected within 12
hours.Finallytransthoracicandtransesophagealechocardio-
graphies were performed.
In patients with positive blood cultures, antibiotic treat-
ment was administered according to results of antibiotic sus-
ceptibility testing. Large spectrum empiric antibiotic treat-
ment was prescribed in patients with culture negative en-
docarditis [6, 8]. Eight patients with methicillin-resistant
Staphylococcus aureus (MRSA) infection were treated with
linezolid, vancomicin, or teicoplanin associated with an ami-
noglycoside.
Surgery was scheduled within seven days from admis-
sion. 32 patients with NVE underwent valve replacement
while in 18 (36%) a conservative surgery with valve repair
had been possible (Table 2(a)). Valve repair was more
frequently performed in mitral valve endocarditis (13/20
patients) than in aortic (2/10) or combined mitral and aortic
valve disease. Homograft replacement of aortic valve and
aortic root has been employed in 12/13 patients with com-
plicated aortic PVE.
Additional operative procedures included the closure of
infection-related ventricular septal defects in 2 patients and
closure of a congenital atrial septal defect in 1 patient. In
one patient with aortic valve endocarditis coronary revas-
cularization with venous graft on right coronary artery was
performed.
After discharge, all patients were admitted to a rehabili-
tation centre and thereafter followed by their general prac-
titioner. Clinical examinations were scheduled (3, 9, 18,
Table 2: (a) Surgical procedures performed in patients with native
(NVE) and prosthetic valve endocarditis (PVE). (b) Indications for
surgery in NVE and PVE.
(a)
Surgical procedure
NVE (Tot = 50, Ao =
20, Mt = 20, Tc = 4,
Mt + Ao = 6)
PVE (Tot = 30,
Ao = 18, Mt = 12)
Aortic valve
replacement 18 7
Mitral valve
replacement 71 0
Mitral and aortic
valve replacement 51
Tricuspid valve
replacement 2—
Mechanical prosthesis 24 10
Biologic prosthesis 8 8
Homograft 1 12
Valve repair 18 0
(b)
NVE (20 Ao/20
Mt/4 Tc/6 Ao + Mt) PVE (18 Ao/12 Mt)
Haemodynamic
instability with or
without cardiogenic
shock
26 10
Perivalvular abscess 1 13
Previous
embolization 83
Vegetations > 10mm 15 4
24 months). The mean follow-up period after hospital
discharge has been 18 months (range 3 to 48 months). In 26
patients not followed at our centre, information on clinical
conditions was obtained through a telephonic question-
naire in which data about survival, hospital readmissions,
recurrences of endocarditis, and exercise capacity at the
time of interview were collected. All patients gave informed
consent to the study at hospital admission, and the study was
approved by the ethical committee of the hospital.
2.1. Statistical Analysis. The quantitative variables are re-
ported as means and standard deviations. In case of not con-
tinuous parameters the frequency of distribution has been
reported.
The statistical analysis of clinical data was carried out by
the Student’s t-test forcontinuous data, while fornot contin-
uous variables χ2 test or Fisher exact test when appropriated
was used.
The analysis of survival was made using the Kaplan-
Meier method, and the diﬀerence between the groups was
analyzed using the log-rank test. A probability value of <.05
was considered statistically signiﬁcant.ISRN Cardiology 3
Table 3: Microorganism responsible for endocarditis in relation to
the type of valve aﬀected.
Aetiologic agent NVE (no 50) PVE (no 30) Total (no 80)
no % no % no %
Staph. aureus 9 18 7 23 16 20
Staph. Epidermidis 3 6 5 17 8 10
O t h e r S t a p h 240 0 2 2 . 5
Strept. faecalis 2 4 5 17 7 8.7
Strept. viridans 4 8 0 0 4 5
Other Strept. 12 24 3 10 15 18.8
Gram-negative 2 4 3 10 5 6.2
Candida 1 2 0 0 1 1.2
Negative blood Colture15 30 7 23 22 27.6
3. Results
3.1. Clinical Characteristics. At hospital admission 56% of
patients was in NYHA functional class III-IV, 30% and 14%
respectively, in class I and in class II.
Predisposing factors, a part from previous valve surgery,
were rarely identiﬁed. Three patients had history of dental
procedures and Streptococcus viridans endocarditis. Two
S. aureus tricuspid valve endocarditis were observed in
intravenous drug addicts. One patient with endocarditis due
to S. bovis was aﬀected by chronic inﬂammatory bowel
disease. For most of late prosthetic valve endocarditis, we
were not able to identify a causal event for the development
of infection. Overall incidence of peripheral embolism
conﬁrmed by instrumental investigations was 35%.
3.2. Etiologic Infective Organisms. Blood cultures allowed
identiﬁcationoftheetiologicagentin58/80patients.Staphy-
lococci were the most common microorganisms isolated in
blood cultures (Table 3). Streptococci were identiﬁed in 26
patients while a Gram-negative was found in 5 patients. One
immune depressed patient had fungal endocarditis (Candida
parapsilosis). Blood cultures were negative in 22 subjects,
15 with native valve disease. Almost all these patients were
referred from peripheral hospitals and previously treated
with large spectrum empiric antibiotic therapy.
3.3. Echocardiographic Characteristics. Echocardiography
performed at admission showed a preserved left ventricular
systolic function (EF > 50%) in 65% of patients. In 31% left
ventricular function was moderately depressed (EF between
35 and 50%). Only 5 patients showed a severe functional
impairment (EF < 35%).
An annular abscess was identiﬁed at TEE in 12/19
patients with aortic PVE and only in 1/19 patient with aortic
NVE.Oneormoremobilevegetationswereidentiﬁedin90%
of NVE. Overall moderate to severe valvular regurgitation
occurred in 81% of patients with mitral valve involvement
and 79% of those with aortic valve endocarditis. More than
trivial tricuspidal regurgitation could be observed in 55% of
patients.
3.4. Indications for Surgery. Hemodynamic impairment
related to severe mitral or aortic valve regurgitation was
the main indication for surgery in 48% of patients. In 15
patients surgery was indicated for perivalvular spreading of
the infection with abscesses (14 subjects, 92% in PVE) or
aortic to right atrium ﬁstula (1 patient). Large vegetations
>10mm diameter (24%) and recurrent embolism were the
other main indications for surgery. All patients underwent
surgery within 7 days after starting antibiotic treatment,
unless impairment of clinical conditions suggested an earlier
solution.
3.5. Hospital Mortality and Morbidity. Of the 80 patients
included in the study two died before surgery, one due
to septic shock and widespread peripheral embolism, the
other suddenly from the rupture of an aortic abscess. In-
hospital postsurgery mortality has been 10.2% (8/78). One
patient died in operating room (mitral valve replacement)
for rupture of the atrioventricular sulcum. The other 7
patients died within the ﬁrst 30 days after surgery, 3 due to
irreversible cardiogenic shock, 3 due to multisystem organ
failure as a result of severe septic shock, and the last one for
rupture of a mycotic aneurism of splenic artery.
Factors closely related to in-hospital mortality were
advanced age, severe depression of left ventricular function,
and ﬁnally clinical and laboratory evidence of severe sepsis
(temperature at admission over 38◦C, WBC > 15000mm3,
serum creatinine > 2,0mg/dL) (Table 4). We did not ﬁnd any
signiﬁcant diﬀerence in hospital survival between native or
PVE, between mitral or aortic valve involvement or ﬁnally
between patients with or without perivalvular involvement.
In patients discharged alive from hospital survival was
95.1% (67 out of 70) at an average followup of 18 months
(Figure 1(a)). Three patients died during followup, one for
lung cancer the other two from refractory heart failure.
Event-free survival (death and endocarditis recurrence) is
reported in Figure 1(b). Endocarditis recurred only in 4
patients: all needed reintervention. Two were intravenous
drug users with recurrence of staphylococci endocarditis on
prosthetic tricuspid valve. In the other 2 biologic aortic
prostheticvalveshowedsevereparavalvularleak,respectively,
3and5monthsaftersurgery.Bloodcultureswerepositivefor
S. aureus in both patients. We did not ﬁnd any signiﬁcant
diﬀerence in survival between native or prosthetic valve
endocarditis (Figures 2(a) and 2(b)).
Survival was not signiﬁcantly diﬀerent between patients
undergoing valve repair and those undergoing valve replace-
ment. In the group of patients selected for valve repair
strategy none had recurrence of endocarditis, and at fol-
lowup echocardiography did not show more than mild
residualregurgitation.Similarlynoneofpatientstreatedwith
homograft implant had postoperative complications.
Surgical treatment led to a signiﬁcant functional im-
provement. At the end of followup 90% of patients dis-
charged alive from hospital were in NYHA class I-II in com-
parison to 58% in the preoperative period. Only 10% had
still a severe functional limitation after surgery (NYHA class
III-IV).4 ISRN Cardiology
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Figure 1: Overall survival (a) and event free-death, endocarditis recurrence-survival (b) in patients discharged alive from hospital.
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Figure 2: Comparison of overall survival (a) and survival in patients discharged alive (b) between patients with NVE and PVE.
4. Discussion
Previous clinical investigations suggested that surgical treat-
ment in active infective endocarditis is associated with a
survival rate ranging from 70 to 85% and with a recurrence
ratebetween8.5and15%[9–11].Theavailabilityofdiﬀerent
surgical solutions (e.g., valve repair or aortic homografts)
other than valve replacement, allowing the choice of the
propertechnicalstrategyinthesinglepatient,mightimprove
results of surgical treatment of active infective endocarditis,
inparticulardecreasingtheriskofinfectiousrecurrencesand
the need for long-term anticoagulation.
Early surgery should be considered the treatment of
choice in active complicated PVE [12] in patients that are
not too sick to represent a prohibitive surgical challenge.
Previous investigations suggested that homograft aortic root
replacement may improve survival rate and in particular
decrease the risk of recurrences [13]. In the study by Lopes
et al. [14] 41 patients with complex PVE were treated with
allograft aortic root replacement. In-hospital mortality has
been 4.8%; two patents needed late reintervention for graft
failure. No patients showed recurrence of endocarditis, and
overall survival at ten years was 79%. The role of homograft
in treatment of aortic endocarditis has been questioned by
Avierinos et al. [15]. The authors did not ﬁnd signiﬁcant
diﬀerence in survival rate in relation between conventional
treatment with valve replacement and the use of homograft.
However the study suﬀered from several methodological
limitations; mainly patients were not randomized, and
most of patients with complicated PVE were treated with
homograft implantation (annular complications were found
in76% ofthehomograftgroupversus30% inconventionally
treated group). The absence of diﬀerences in long term
outcomesuggeststhathomograftsmaybea-safertherapeutic
option in patients with more severe and advanced disease al-
though some concerns still regard their durability. In presentISRN Cardiology 5
Table 4: In-hospital outcome in relation to demographic, hemodynamic, echocardiographic, and clinical and laboratory parameters.
Parameter Patients discharged alive Patients died after surgery during hospitalization tP
(70) (8)
Age (years) 58.1 ± 16.3 69.7 ± 10 2.194 .03
Heart rate (bpm) 87 ± 19 105 ± 20 2.67 .009
Systolic heart pressure (mmHg) 127 ± 22 130 ± 23 0.384 .710
Diastolic heart pressure (mmHg) 67 ±16 71 ± 16 0.69 .492
LV Ejection Fraction (%) X2
>50% 57 1
26.6 <.0001 35–50% 12 4
<35% 1 3
Aortic regurgitation X2
3+-4+ 31 2
1,37 .50 <2+ 22 4
01 7 2
Mitral regurgitation X2
3+-4+ 30 3
0.08 .95 <2+ 24 3
01 6 2
Temperature ◦C X2
>38 12 5
9,93 .007 37-38 31 3
<37 27 0
Total WBC/mm3 X2
>15,000 6 5
21.4 <.001 10,000–15,000 15 3
<10,000 49 0
Hemoglobin g/dl X2
<10 22 6
6.8 .04 10–12 22 2
>12 26 0
Creatinine mg/dl X2
>27 1
20.33 <.001 1.5–2 5 5
<1.5 58 2
C-reactive protein (mg/l) Fisher ex
n.s. >10 23 3 text
<10 47 5 1.0
investigation 13/14 (92%) patients with complicated aortic
endocarditis (12 PVE, 1 NVE) were treated with aortic hom-
ograft. At followup none of these patients died or showed
recurrence.
Valverepair,inparticularinpatientswithmitralvalveen-
docarditis, is considered a valuable therapeutic option when
technically feasible. Conservative surgery allows to decrease
the risks related to prolonged anticoagulation and the unfa-
vourable left ventricular geometric changes associated with
valve replacement [16]. In our study in 65% (13/20) patients
with isolated mitral NVE has been possible to preserve the
valve. Moreover in 2 patients with tricuspid, 2 with aortic,
and 1 with combined aortic and mitral valve involvement
valve repair was preferred to valve replacement. None of the
patients undergoing NVE reparative surgery had signiﬁcant
postoperative complications. Only one patient undergoing
mitral valve repair had mild regurgitation at 64 week
followup.
Overall mortality in patients discharged alive from hos-
pital has been less than 5%, at an average followup of 18
months. In particular patients undergoing valve repair and
homograft implant were all alive and had no recurrent endo-
carditis. The severity of the septic state at hospital admission
is an important prognostic factor for perioperative mortality
with a more relevant clinical impact than the degree of he-
modynamic impairment.6 ISRN Cardiology
4.1. Study Limitations. Present investigation is a relatively
small single centre observational study of patients under-
going surgery for active infective endocarditis. The length
of followup is limited (average 18 months), and we are
aware that homograft degeneration, often leading to the
need of reintervention, may be observed during longer
follow-up periods. However homograft-treated patients was
a group with complicated endocarditis at high risk of
death or recurrence after conventional treatment with valve
replacement. In our series at followup patients treated with
homograft were all alive and free from infective recurrences.
Seventy-ﬁve percent of patients included in present in-
vestigation were referred for surgery to our centre from pe-
ripheral hospitals. Preselection of patients may have con-
tributed to the invoice for surgery of patients with more
severe disease but on average younger, with a lower number
of comorbidities and at overall lower surgical risk in com-
parison to the whole population of patients suﬀering from
endocarditis. This hypothesis is in agreement with the obser-
vations of the International Collaboration in Endocarditis
Prospective Cohort database [5]. The availability of several
surgical solutions (e.g., valve repair or aortic homografts)
other than valve replacement, allowing the choice of the
proper technical strategy in the single patient, is associated
with an acceptable operative risk and with signiﬁcant im-
provement in midterm survival and decreased risk of recur-
rences.
References
[1] G. Habib, C. Tribouilloy, F. Thuny et al., “Prosthetic valve
endocarditis: who needs surgery? A multicentre study of 104
cases,” Heart, vol. 91, no. 7, pp. 954–959, 2005.
[2] I. Anguera, J. M. Miro, A. Evangelista et al., “Periannular com-
plications in infective endocarditis involving native aortic
valves,” American Journal of Cardiology,v o l .9 8 ,n o .9 ,p p .
1254–1260, 2006.
[3] C. M. Oakley and R. J. C. Hall, “Endocarditis: problems -
patients being treated for endocarditis and not doing well,”
Heart, vol. 85, no. 4, pp. 470–474, 2001.
[4] F. Delahaye, A. Bannay, C. Selton-Suty et al., “Longterm mor-
tality of infective endocarditis in a population-based cohort
study conducted between 1999 and 2005 in France,” European
Heart Journal, vol. 29, 2008, (Abstract Supplement ), 782.
[5] D. R. Murdoch, R. G. Corey, B. Hoen et al., “Clinical presen-
tation, etiology, and outcome of infective endocarditis in the
21stcentury:theInternationalCollaborationonEndocarditis-
Prospective Cohort Study,” Archives of Internal Medicine, vol.
169, no. 5, pp. 463–473, 2009.
[6] L. M. Baddour, W. R. Wilson, A. S. Bayer et al., “Infective
endocarditis: diagnosis, antimicrobial therapy, and manage-
ment of complications: a statement for healthcare profession-
als from the Committee on Rheumatic Fever, Endocarditis,
and Kawasaki Disease, Council on Cardiovascular Disease in
the Young, and the Councils on Clinical Cardiology, Stroke,
and Cardiovascular Surgery and Anesthesia, American Heart
Association: endorsed by the Infectious Diseases Society of
America,” Circulation, vol. 111, no. 23, pp. e394–e434, 2005.
[7] D. Horstkotte, F. Follath, E. Gutschik et al., “Guidelines on
prevention, diagnosis and treatment of infective endocarditis
executive summary: the task force on infective endocarditis of
the European Society of Cardiology,” European Heart Journal,
vol. 25, no. 3, pp. 267–276, 2004.
[8] A. Wang, E. Athan, P. A. Pappas et al., “Contemporary clinical
proﬁle and outcome of prosthetic valve endocarditis,” Journal
oftheAmericanMedicalAssociation,vol.297,no.12,pp.1354–
1361, 2007.
[9] P. Tornos, B. Iung, G. Permanyer-Miralda et al., “Infective
endocarditis in Europe: lessons from the Euro Heart Survey,”
Heart, vol. 91, no. 5, pp. 571–575, 2005.
[10] J. Bishara, L. Leibovici, D. Gartman-Israel et al., “Long-term
outcome of infective endocarditis: the impact of early surgical
intervention,” Clinical Infectious Diseases, vol. 33, no. 10, pp.
1636–1643, 2001.
[11] T. E. David, “Surgical treatment of aortic valve endocarditis,”
Cardiac Surgery in Adult, vol. 2, pp. 857–866, 2003.
[12] F. J. Baumgartner, B. O. Omari, J. M. Robertson, R. J. Nelson,
A. Pandya, and J. C. Milliken, “Annular abscesses in surgi-
cal endocarditis: anatomic, clinical, and operative features,”
Annals of Thoracic Surgery, vol. 70, pp. 442–447, 2000.
[13] I. Anguera, J. M. Miro, J. A. San Roman et al., “Periannular
complications in infective endocarditis involving prosthetic
aortic valves,” American Journal of Cardiology, vol. 98, no. 9,
pp. 1261–1268, 2006.
[14] S. Lopes, P. Calvinho, F. de Oliveira, and M. Antunes, “Allo-
graft aortic root replacement in complex prosthetic endo-
carditis,” European Journal of Cardio-Thoracic Surgery, vol. 32,
no. 1, pp. 126–130, 2007.
[15] J. F. Avierinos, F. Thuny, V. Chalvignac et al., “Surgical
treatment of active aortic endocarditis: homografts are not the
cornerstone of outcome,” Annals of Thoracic Surgery, vol. 84,
no. 6, pp. 1935–1942, 2007.
[16] H.H.H.Feringa,L.J.Shaw,D.Poldermansetal.,“Mitralvalve
repair and replacement in endocarditis: a systematic review of
literature,” Annals of Thoracic Surgery, vol. 83, no. 2, pp. 564–
570, 2007.